---
title: "Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286437362.md"
description: "Laekna, Inc. has scheduled its annual general meeting for June 5, 2026, in Shanghai to seek shareholder approval for its 2025 audited financial statements, the re-election of directors, and to authorize share issuance up to 20% of its issued share capital. The company aims to enhance its capital flexibility for future growth. The latest analyst rating for Laekna's stock (HK:2105) is a Buy, with a price target of HK$24.16."
datetime: "2026-05-14T15:07:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286437362.md)
  - [en](https://longbridge.com/en/news/286437362.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286437362.md)
---

# Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Laekna, Inc. ( (HK:2105) ).

Laekna, Inc. has called its annual general meeting for 5 June 2026 in Shanghai to seek shareholder approval of its 2025 audited financial statements and the re-election of two executive directors and one independent non-executive director. The company will also request authorization for the board to set director and auditor remuneration and to reappoint KPMG as auditor.

In addition, the board is asking shareholders to grant a general mandate allowing directors to issue, allot, or deal with additional shares and related securities, up to 20% of the company’s issued share capital, excluding treasury shares. If approved, this mandate would give Laekna increased flexibility to raise capital and manage its equity structure, potentially supporting future growth initiatives and strategic financing activities.

The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.

**More about Laekna, Inc.**

Laekna, Inc. is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange. Operating in the biopharmaceutical sector, it focuses on developing and commercializing innovative therapies, with its corporate presence and shareholder base centered in mainland China and Hong Kong capital markets.

**Average Trading Volume:** 2,661,812

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$5.82B

For an in-depth examination of 2105 stock, go to TipRanks’ Overview page.

### Related Stocks

- [02105.HK](https://longbridge.com/en/quote/02105.HK.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [520500.CN](https://longbridge.com/en/quote/520500.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [CICC Sticks to Their Buy Rating for Laekna, Inc. (2105)](https://longbridge.com/en/news/283298518.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)
- [Bank of America Securities Reaffirms Their Buy Rating on Laekna, Inc. (2105)](https://longbridge.com/en/news/285640720.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)